Roche sweetens bid for Illumina

Roche yesterday increased its bid for US gene sequencing company Illumina to $6.7bn (£4.2bn) in hopes of winning over shareholders ahead of Illumina’s AGM next month. In a statement yesterday Roche, the Swiss drug maker, said it is now offering $51.00 per share, up from an initial $44.50 that was dismissed by Illumina for being too low.

Its offer expires on 20 April.